

[~118H5397]

  
(Original Signature of Member)

119TH CONGRESS  
1ST SESSION

**H. R.** \_\_\_\_\_

To amend title XVIII of the Social Security Act to provide coverage of external infusion pumps and non-self-administrable home infusion drugs under the Medicare program.

---

IN THE HOUSE OF REPRESENTATIVES

Mr. FITZPATRICK introduced the following bill; which was referred to the Committee on \_\_\_\_\_

---

**A BILL**

To amend title XVIII of the Social Security Act to provide coverage of external infusion pumps and non-self-administrable home infusion drugs under the Medicare program.

1 *Be it enacted by the Senate and House of Representa-*  
2 *tives of the United States of America in Congress assembled,*

3 **SECTION 1. SHORT TITLE.**

4 This Act may be cited as the “Joe Fiandra Access  
5 to Home Infusion Act of 2025”.

1 **SEC. 2. MEDICARE COVERAGE OF EXTERNAL INFUSION**  
2 **PUMPS AND NON-SELF-ADMINISTRABLE**  
3 **HOME INFUSION DRUGS.**

4 (a) IN GENERAL.—Section 1861(n) of the Social Se-  
5 curity Act (42 U.S.C. 1395x(n)) is amended by adding  
6 at the end the following new sentence: “Beginning with  
7 the first calendar quarter beginning on or after the date  
8 that is 1 year after the date of the enactment of this sen-  
9 tence, an external infusion pump and associated home in-  
10 fusion drug (as defined in subsection (iii)(3)(C)) or other  
11 associated supplies that do not meet the appropriate for  
12 use in the home requirement applied to the definition of  
13 durable medical equipment under section 414.202 of title  
14 42, Code of Federal Regulations (or any successor to such  
15 regulation) shall be treated as meeting such requirement  
16 if each of the following criteria is satisfied:

17 “(1) The prescribing information approved by  
18 the Food and Drug Administration for the home in-  
19 fusion drug associated with the pump instructs that  
20 the drug should be administered by or under the su-  
21 pervision of a health care professional.

22 “(2) A qualified home infusion therapy supplier  
23 (as defined in subsection (iii)(3)(D)) administers or  
24 supervises the administration of the drug or biologi-  
25 cal in a safe and effective manner in the patient’s  
26 home (as defined in subsection (iii)(3)(B)).

1           “(3) The prescribing information described in  
2           paragraph (1) instructs that the drug should be in-  
3           fused at least 12 times per year—

4                   “(A) intravenously or subcutaneously; or

5                   “(B) at infusion rates that the Secretary  
6           determines would require the use of an external  
7           infusion pump.”.

8           (b) COST SHARING NOTIFICATION.—The Secretary  
9           of Health and Human Services shall ensure that patients  
10          are notified of the cost sharing for electing home infusion  
11          therapy compared to other applicable settings of care for  
12          the furnishing of infusion drugs under the Medicare pro-  
13          gram.